Marieta Toma

University of Bonn — Germany

Medicine · Health Sciences

33h-index3.8kcitations269works2.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bladder and Urothelial Cancer Treatments(55), Epigenetics and DNA Methylation(46), Prostate Cancer Treatment and Research(42), Renal cell carcinoma treatment(31), Prostate Cancer Diagnosis and Treatment(22)

Publications269 total

Neue WHO-Klassifikation der Nierenzelltumore – Implikationen für eine individuelle Therapieentscheidung und die adäquate Erkennung von erblichen Nierenzellkarzinomen
Aktuelle Urologie·2025
SPACEc: a streamlined, interactive Python workflow for multiplexed image processing and analysis
Nature Communications·2025· 3 citedOpen Access
Supplementary Data TS1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
2025Open Access
Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
2025Open Access
Supplementary Data TS2 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
2025Open Access
Figure S1 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025· 1 citedOpen Access
Table S3 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Table S4 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Table S5 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Data from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Table S1 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Figure S2 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Figure S3 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Table S7 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Table S6 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Table S2 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Figure S4 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
TMOD-28. Core2Edge: A human glioblastoma organoid and brain slice co-culture model capturing tumor infiltration and transcriptional heterogeneity from core to single-cell dispersion
Neuro-Oncology·2025Open Access
Flow cytometry protocol for cell death analysis in glioblastoma organoids: A technical note
PLoS ONE·2025Open Access
Reticulocalbin-1 in clear cell renal cell carcinoma: clinical and functional evidence for its role as a biomarker and potential therapeutic target
BMC Cancer·2025· 2 citedOpen Access
page 1 of 14Next →

Frequent Co-authors

Manfred P. Wirth(18), Glen Kristiansen(15), Gustavo Baretton(14), Jörg Ellinger(12), Stefan Zastrow(11), Niklas Klümper(9), Manuel Ritter(9), Yuri Tolkach(7), Michael Hölzel(7), Matthias Meinhardt(7), Susanne Fuessel(7), Hartwig Huland(6), S. Füssel(6), Arndt Hartmann(5), Daniela Wuttig(5), Michael Froehner(5), Michael H. Muders(5), Martin G. Friedrich(4), Christian P. Strassburg(4), Maria A. González-Carmona(4)